Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Brain Neoplasms 9Squamous Cell Carcinoma of Head and Neck 7Glioblastoma 7Polycythemia Vera 6Gliosarcoma 6Leukemia 5Head and Neck Neoplasms 5Meningioma 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Acute 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Neoplasms 3Myelodysplastic Syndromes 3Laryngeal Neoplasms 3Central Nervous System Neoplasms 3Thrombocythemia, Essential 2Stomach Neoplasms 2Salivary Gland Neoplasms 2Pharyngeal Neoplasms 2Paranasal Sinus Neoplasms 2Oropharyngeal Neoplasms 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Hypopharyngeal Neoplasms 2Glioma 2Congenital Abnormalities 2Carcinoma, Squamous Cell 2Astrocytoma 2

Interventions

Temozolomide 66Radiotherapy 34Carboplatin 22Carmustine 21Bevacizumab 21Irinotecan 18Filgrastim 18Surgical Procedures, Operative 14Vincristine 11Peripheral Blood Stem Cell Transplantation 11Etoposide 11Radiation 10O(6)-benzylguanine 10Magnetic Resonance Spectroscopy 9Lomustine 9Procarbazine 8Erlotinib Hydrochloride 8sargramostim 7IL13-PE38 7Everolimus 7Cyclophosphamide 7Chemotherapy, Adjuvant 7Thiotepa 6Radiotherapy, Intensity-Modulated 6Imatinib Mesylate 6Granulocyte Colony-Stimulating Factor 6Drug Therapy 6Cisplatin 6temsirolimus 5antineoplaston AS 2-1 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Astrocytoma × Hydroxyurea × Clear all
NCT00387933 2015-10-14

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

Duke University

Phase 1 Completed
37 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00154375 2011-04-26

Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma

Novartis

Phase 3 Completed
240 enrolled 8 charts
CNS

Adenocarcinoma, Astrocytoma, Brain Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡